Published in Antimicrob Agents Chemother on July 01, 1999
Contribution of a response regulator to the virulence of Streptococcus pneumoniae is strain dependent. Infect Immun (2003) 1.23
Potent small-molecule suppression of oxacillin resistance in methicillin-resistant Staphylococcus aureus. Angew Chem Int Ed Engl (2012) 1.14
Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother (2004) 1.13
Broad spectrum pro-quorum-sensing molecules as inhibitors of virulence in vibrios. PLoS Pathog (2012) 1.11
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother (2006) 1.07
MC21-A, a bactericidal antibiotic produced by a new marine bacterium, Pseudoalteromonas phenolica sp. nov. O-BC30(T), against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.04
Small molecule suppression of carbapenem resistance in NDM-1 producing Klebsiella pneumoniae. ACS Med Chem Lett (2012) 1.04
Antistaphylococcal and biofilm inhibitory activities of acetyl-11-keto-β-boswellic acid from Boswellia serrata. BMC Microbiol (2011) 1.00
Biological properties of novel antistaphylococcal quinoline-indole agents. Antimicrob Agents Chemother (2003) 0.97
Different modes of action of naphthyridones in gram-positive and gram-negative bacteria. Antimicrob Agents Chemother (2006) 0.93
Identification and analysis of bacterial protein secretion inhibitors utilizing a SecA-LacZ reporter fusion system. Antimicrob Agents Chemother (2000) 0.92
Identification and characterization of new inhibitors of the Escherichia coli MurA enzyme. Antimicrob Agents Chemother (2001) 0.90
Novel rapidly diversifiable antimicrobial RNA polymerase switch region inhibitors with confirmed mode of action in Haemophilus influenzae. J Bacteriol (2012) 0.89
New class of competitive inhibitor of bacterial histidine kinases. J Bacteriol (2005) 0.88
Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS One (2015) 0.86
Identification of a dithiazoline inhibitor of Escherichia coli L,D-carboxypeptidase A. Antimicrob Agents Chemother (2005) 0.85
In vitro validation of acetyltransferase activity of GlmU as an antibacterial target in Haemophilus influenzae. J Biol Chem (2011) 0.85
Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes. Antimicrob Agents Chemother (2008) 0.84
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914. J Biol Chem (2015) 0.84
A screen for and validation of prodrug antimicrobials. Antimicrob Agents Chemother (2013) 0.83
Redox-active compounds with a history of human use: antistaphylococcal action and potential for repurposing as topical antibiofilm agents. J Antimicrob Chemother (2014) 0.82
Isolation and characterization of signermycin B, an antibiotic that targets the dimerization domain of histidine kinase WalK. Antimicrob Agents Chemother (2012) 0.82
Lactoferricin B inhibits the phosphorylation of the two-component system response regulators BasR and CreB. Mol Cell Proteomics (2011) 0.82
Prediction of the mechanism of action of fusaricidin on Bacillus subtilis. PLoS One (2012) 0.81
The role of a novel auxiliary pocket in bacterial phenylalanyl-tRNA synthetase druggability. J Biol Chem (2014) 0.81
Polyphenolic extract from maple syrup potentiates antibiotic susceptibility and reduces biofilm formation of pathogenic bacteria. Appl Environ Microbiol (2015) 0.79
Antibacterial and anti-biofilm activities of thiazolidione derivatives against clinical staphylococcus strains. Emerg Microbes Infect (2015) 0.79
Elucidation of the Mode of Action of a New Antibacterial Compound Active against Staphylococcus aureus and Pseudomonas aeruginosa. PLoS One (2016) 0.79
Mechanistic insight into inhibition of two-component system signaling. Medchemcomm (2012) 0.78
Putative histidine kinase inhibitors with antibacterial effect against multi-drug resistant clinical isolates identified by in vitro and in silico screens. Sci Rep (2016) 0.78
In vitro efficacy of diclofenac against Listeria monocytogenes. Eur J Clin Microbiol Infect Dis (2008) 0.78
Antifungal properties and target evaluation of three putative bacterial histidine kinase inhibitors. Antimicrob Agents Chemother (1999) 0.77
Repurposing Toremifene for Treatment of Oral Bacterial Infections. Antimicrob Agents Chemother (2017) 0.76
Nordihydroguaiaretic acid enhances the activities of aminoglycosides against methicillin- sensitive and resistant Staphylococcus aureus in vitro and in vivo. Front Microbiol (2015) 0.75
Effect of nisin and perilla oil combination against Listeria monocytogenes and Staphylococcus aureus in milk. J Food Sci Technol (2016) 0.75
In vitro bactericidal activity of 4- and 5-chloro-2-hydroxy-N-[1-oxo-1-(phenylamino)alkan-2-yl]benzamides against MRSA. Biomed Res Int (2015) 0.75
Protein phosphorylation and regulation of adaptive responses in bacteria. Microbiol Rev (1989) 20.50
Communication modules in bacterial signaling proteins. Annu Rev Genet (1992) 14.32
The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol (1992) 4.99
Characterization of the gene for a protein kinase which phosphorylates the sporulation-regulatory proteins Spo0A and Spo0F of Bacillus subtilis. J Bacteriol (1989) 4.20
Negative control of bacterial DNA replication by a cell cycle regulatory protein that binds at the chromosome origin. Proc Natl Acad Sci U S A (1998) 3.85
Structural conservation in the CheY superfamily. Biochemistry (1993) 3.55
Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother (1991) 3.18
Compilation of all genes encoding two-component phosphotransfer signal transducers in the genome of Escherichia coli. DNA Res (1997) 3.07
Protein histidine kinases and signal transduction in prokaryotes and eukaryotes. Trends Genet (1994) 2.85
The mechanism of the bacteriostatic action of tetrachlorosalicylanilide: a Membrane-active antibacterial compound. J Gen Microbiol (1968) 2.81
Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother (1990) 2.40
Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J Bacteriol (1997) 2.29
A two-component signal-transducing system is involved in competence and penicillin susceptibility in laboratory mutants of Streptococcus pneumoniae. Mol Microbiol (1994) 2.22
Structure of the Mg(2+)-bound form of CheY and mechanism of phosphoryl transfer in bacterial chemotaxis. Biochemistry (1993) 2.15
Genes involved in production of plasmidlike forms by a Bacteroides conjugal chromosomal element share amino acid homology with two-component regulatory systems. J Bacteriol (1992) 2.15
Mechanism of autophosphorylation of Escherichia coli nitrogen regulator II (NRII or NtrB): trans-phosphorylation between subunits. J Bacteriol (1993) 2.13
Compilation of all genes encoding bacterial two-component signal transducers in the genome of the cyanobacterium, Synechocystis sp. strain PCC 6803. DNA Res (1996) 1.98
Signal transduction via the histidyl-aspartyl phosphorelay. Genes Cells (1997) 1.96
Molecular recognition in signal transduction: the interaction surfaces of the Spo0F response regulator with its cognate phosphorelay proteins revealed by alanine scanning mutagenesis. J Mol Biol (1997) 1.86
The two-component system. Regulation of diverse signaling pathways in prokaryotes and eukaryotes. Plant Physiol (1998) 1.72
Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry (1996) 1.71
Inhibitors of two-component signal transduction systems: inhibition of alginate gene activation in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (1993) 1.69
Antibacterial agents that inhibit two-component signal transduction systems. Proc Natl Acad Sci U S A (1998) 1.53
Histidine kinases in signal transduction pathways of eukaryotes. J Cell Sci (1997) 1.47
Structure of the CheY-binding domain of histidine kinase CheA in complex with CheY. Nat Struct Biol (1998) 1.43
Insights into multistep phosphorelay from the crystal structure of the C-terminal HPt domain of ArcB. Cell (1997) 1.42
Expression of the AsbA1, OXA-12, and AsbM1 beta-lactamases in Aeromonas jandaei AER 14 is coordinated by a two-component regulon. J Bacteriol (1997) 1.36
Flow cytometric assessment of Escherichia coli and Salmonella typhimurium starvation-survival in seawater using rhodamine 123, propidium iodide, and oxonol. Appl Environ Microbiol (1995) 1.34
Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. J Med Chem (1998) 1.31
Mechanism of membrane damage induced by the amphipathic peptides gramicidin S and melittin. Biochim Biophys Acta (1989) 1.16
Identification and characterization of a two-component regulatory system involved in invasion of eukaryotic cells and heavy-metal resistance in Burkholderia pseudomallei. Infect Immun (1997) 1.14
Crystal structure of a phosphatase-resistant mutant of sporulation response regulator Spo0F from Bacillus subtilis. Structure (1996) 1.13
A second two-component regulatory system of Bordetella bronchiseptica required for bacterial resistance to oxidative stress, production of acid phosphatase, and in vivo persistence. Infect Immun (1998) 1.11
Mechanism of action of uncouplers of oxidative phosphorylation. Biochemistry (1971) 1.02
Purification and characterization of a hemolysin produced by Vibrio mimicus. Infect Immun (1997) 0.89
Mechanistic studies and biological activity of bioxalomycin alpha 2, a novel antibiotic produced by Streptomyces viridodiastaticus subsp. "litoralis" LL-31F508. Antimicrob Agents Chemother (1994) 0.88
Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel. Bioorg Med Chem Lett (1998) 0.87
How anthelmintics help us to understand helminths. Parasitology (1985) 0.83
Flukicidal action of closantel against immature and mature Fasciola hepatica in experimentally infected rats and sheep. Res Vet Sci (1988) 0.79
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother (2001) 16.97
Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother (1982) 9.58
Carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother (1997) 7.17
Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother (1997) 7.07
Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA (1999) 5.26
Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother (1989) 3.96
Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. Structure (1996) 3.75
Monocyclic beta-lactam antibiotics produced by bacteria. Nature (1981) 3.61
Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents Chemother (1996) 3.44
Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother (1992) 3.31
Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate. Antimicrob Agents Chemother (1994) 3.26
Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria. Antimicrob Agents Chemother (1982) 3.24
Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid-mediated beta-lactamase with two molecular variants. Antimicrob Agents Chemother (1994) 3.09
Methodology for the study of beta-lactamases. Antimicrob Agents Chemother (1986) 2.82
Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae. Antimicrob Agents Chemother (1985) 2.81
Monobactams--monocyclic beta-lactam antibiotics produced by bacteria. J Antimicrob Chemother (1981) 2.68
SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother (1995) 2.66
Effective cooling allows sonication to be used for liberation of beta-lactamases from gram negative bacteria. J Antimicrob Chemother (1989) 2.52
Substitution of lysine at position 104 or 240 of TEM-1pTZ18R beta-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry (1991) 2.49
Localization of labile posttranslational modifications by electron capture dissociation: the case of gamma-carboxyglutamic acid. Anal Chem (1999) 2.43
Biochemical characterization of the metallo-beta-lactamase CcrA from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother (1992) 2.40
First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother (2005) 2.29
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother (2001) 2.21
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Cloning and expression of a cloxacillin-hydrolyzing enzyme and a cephalosporinase from Aeromonas sobria AER 14M in Escherichia coli: requirement for an E. coli chromosomal mutation for efficient expression of the class D enzyme. Antimicrob Agents Chemother (1994) 2.10
Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences. Antimicrob Agents Chemother (1993) 2.03
The AUDIT alcohol consumption questions: reliability, validity, and responsiveness to change in older male primary care patients. Alcohol Clin Exp Res (1998) 1.88
Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrob Agents Chemother (2001) 1.81
Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli isolates producing TEM-10 and TEM-43 beta-lactamases from St. Louis, Missouri. Antimicrob Agents Chemother (1998) 1.77
Antimicrobial resistance in anaerobes. Clin Infect Dis (1997) 1.73
Identification of TEM-26 beta-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother (1994) 1.67
Properties of a class C beta-lactamase from Serratia marcescens. Biochem J (1986) 1.66
Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases. J Antimicrob Chemother (1995) 1.59
In vitro evaluation of tigemonam, a novel oral monobactam. Antimicrob Agents Chemother (1987) 1.59
TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1996) 1.56
Antibacterial agents that inhibit two-component signal transduction systems. Proc Natl Acad Sci U S A (1998) 1.53
Is it important to identify extended-spectrum beta-lactamase-producing isolates? Eur J Clin Microbiol Infect Dis (1996) 1.49
SAR studies of diaryltriazoles against bacterial two-component regulatory systems and their antibacterial activities. Bioorg Med Chem Lett (1998) 1.42
Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 1.40
The human cytomegalovirus UL97 protein is phosphorylated and a component of virions. Virology (1997) 1.40
Medical risks for women who drink alcohol. J Gen Intern Med (1998) 1.39
Avirulent Salmonella typhimurium delta cya delta crp oral vaccine strains expressing a streptococcal colonization and virulence antigen. Vaccine (1988) 1.38
Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. J Med Chem (1998) 1.31
Antimicrobial resistance in Bacteroides. Clin Infect Dis (1993) 1.31
beta-Lactamase inhibitors in perspective. J Antimicrob Chemother (1983) 1.25
Biochemical characterization of the carbapenem-hydrolyzing beta-lactamase AsbM1 from Aeromonas sobria AER 14M: a member of a novel subgroup of metallo-beta-lactamases. FEMS Microbiol Lett (1996) 1.23
Potential of Escherichia coli isolated from nature to propagate cloning vectors. Nature (1980) 1.20
Coordinate expression of ribosomal protein genes during Xenopus development. Dev Biol (1985) 1.19
Contribution of enzymatic properties, cell permeability, and enzyme expression to microbiological activities of beta-lactams in three Bacteroides fragilis isolates that harbor a metallo-beta-lactamase gene. Antimicrob Agents Chemother (1994) 1.17
The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. Bioorg Med Chem Lett (2000) 1.16
Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis (1999) 1.15
Proteolytic activity of human cytomegalovirus UL80 protease cleavage site mutants. J Virol (1994) 1.14
Penicillin-binding proteins and induction of AmpC beta-lactamase. Antimicrob Agents Chemother (1997) 1.13
Polio, war and peace. Bull World Health Organ (2000) 1.11
Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis (2000) 1.09
Improved sensitivity in assays for binding of novel beta-lactam antibiotics to penicillin-binding proteins of Escherichia coli. Antimicrob Agents Chemother (1987) 1.08
Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys (1997) 1.07
Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother (1997) 1.03
Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob Agents Chemother (2001) 0.99
Screening and characterization of enzyme inhibitors as drug candidates. Drug Metab Rev (1983) 0.95
Neurons and ECM regulate occludin localization in brain endothelial cells. Neuroreport (2000) 0.94
Molecular cloning and functional analysis of mouse C-terminal kinesin motor KifC3. Mol Cell Biol (2001) 0.92
Identification and characterization of new inhibitors of the Escherichia coli MurA enzyme. Antimicrob Agents Chemother (2001) 0.90
Crystal structures of the cadmium- and mercury-substituted metallo-beta-lactamase from Bacteroides fragilis. Protein Sci (1997) 0.89
Amp C beta-lactamase-producing Escherichia coli in neonatal meningitis: diagnostic and therapeutic challenge. J Perinatol (2006) 0.88
Two new inhibitors of phospholipase A2 produced by Penicillium chermesinum. Taxonomy, fermentation, isolation, structure determination and biological properties. J Antibiot (Tokyo) (1985) 0.87
Detection of multiresistant ceftazidime-susceptible Klebsiella pneumoniae isolates lacking TEM-26 after class restriction of cephalosporins. Microb Drug Resist (2000) 0.86
Deuterium isotope effects on initial rates of the liver alcohol dehydrogenase reaction. Biochemistry (1973) 0.86
SQ 26,180, a novel monobactam. I Taxonomy, fermentation and biological properties. J Antibiot (Tokyo) (1982) 0.86
EM5400, a family of monobactam antibiotics produced by Agrobacterium radiobacter. I. Taxonomy, fermentation and biological properties. J Antibiot (Tokyo) (1982) 0.86
Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. Antiviral Res (2001) 0.85
Internalization and nuclear localization of interleukin 1 are not sufficient for function. Cell Growth Differ (1991) 0.85
Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess. Antimicrob Agents Chemother (1999) 0.85
Oxacillin hydrolysis by the LCR-1 beta-lactamase. Antimicrob Agents Chemother (1995) 0.85
Two new monobactam antibiotics produced by a Flexibacter sp. I. Taxonomy, fermentation, isolation and biological properties. J Antibiot (Tokyo) (1983) 0.84
Muraceins--muramyl peptides produced by Nocardia orientalis as angiotensin-converting enzyme inhibitors. I. Taxonomy, fermentation and biological properties. J Antibiot (Tokyo) (1984) 0.83
Low back pain. Serial epidural injections effective. BMJ (1993) 0.83
Comparison of broth microdilution, agar dilution, and Etest for susceptibility testing of doripenem against gram-negative and gram-positive pathogens. J Clin Microbiol (2010) 0.83
Inhibition of Escherichia coli TEM-2 beta-lactamase by the sulfated compounds izumenolide, panosialin and sodium dodecyl sulfate. J Antibiot (Tokyo) (1980) 0.83
Izumenolide-a novel beta-lactamase inhibitor produced by Micromonospora. II. Biological properties. J Antibiot (Tokyo) (1980) 0.82
Rapid methods for screening low molecular mass compounds non-covalently bound to proteins using size exclusion and mass spectrometry applied to inhibitors of human cytomegalovirus protease. J Mass Spectrom (1998) 0.82
Activity of sulfa drugs and dihydrofolate reductase inhibitors against Candida albicans. Experientia (1982) 0.82
Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties. Antimicrob Agents Chemother (1999) 0.81
The expanded scapular flap. Plast Reconstr Surg (1995) 0.80
Evaluation of enzyme inhibition data in screening for new drugs. Drugs Exp Clin Res (1986) 0.80
Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Antiviral Res (2001) 0.80
Inhibition of herpes simplex virus type 1 DNA polymerase by the natural product oosporein. J Antibiot (Tokyo) (1992) 0.79
Functional feature of a novel model of blood brain barrier: studies on permeation of test compounds. J Control Release (2001) 0.79
In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother (1996) 0.79
Inhibition of protein synthesis in reticulocyte lysates by a double-stranded RNA component in HeLa mRNA. Biochem Biophys Res Commun (1983) 0.78
Studies on the mechanisms of neurulation in the chick: morphometric analysis of force distribution within the neuroepithelium during neural tube formation. J Exp Zool (1987) 0.78
The natural history of sciatica: a prospective radiological study. Clin Radiol (1992) 0.78
Assessment and treatment of facial deformity resulting from radiation to the orbital area in childhood. Plast Reconstr Surg (1996) 0.78
Solute effects on the mechanical properties of arterial elastin. Connect Tissue Res (1982) 0.77
Deuterium effects on binding of reduced coenzyme alcohol dehydrogenase isoenzyme EE. Science (1971) 0.77
Synergistic effects of laminin and thyroid hormones on neuron polarity in culture. Neuroreport (1999) 0.77
Bilateral retinoblastoma presenting at retinopathy of prematurity screening. Arch Dis Child Fetal Neonatal Ed (2010) 0.77